A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
← catalyst calendarNCT07426380 · readout ≤ 73 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
28estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-24 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Kidney Disease
- Renal Insufficiency Chronic
- Kidney Failure, Chronic
- Renal Impairment
- Renal Insufficiency
- End Stage Kidney Disease
Intervention
- Drug: LY3841136 — also filed as Eloralintide
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136
measured Predose on Day 1 up to Day 71
PK: Maximum Observed Drug Concentration (Cmax) of LY3841136
measured Predose on Day 1 up to Day 71
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed